Ophthalmology Times - Ophthalmology news, articles, and events
Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.
Ophthalmologists: Castor oil shouldn’t be rubbed in the eyes, no …
Aug 8, 2023 · Ophthalmologists are issuing a warning not to use castor oil as a way to treat vision problems amid claims circulating on TikTok. In its heyday, castor oil was considered a jack-of-all-trades home remedy, used as a laxative, a moisturizer and …
Physicians sort out pros and cons of several new IOLs on the market
Nov 12, 2021 · Monofocal IOLs The monofocal category was expanded recently with 2 novel aspheric hydrophobic acrylic lenses—the TECNIS Eyhance (ICB00, Johnson + Johnson Vision) and the Clareon (Alcon). The Eyhance IOL has extended depth of focus (EDoF)-like qualities through the design of the central 1 mm of its optic. However, the Eyhance was not approved as an EDoF lens and surgeons cannot charge a ...
Breaking down the dorzolamide shortage - Ophthalmology Times
Aug 9, 2019 · Editor’s Note: Welcome to “Let's Chat,” a blog series featuring contributions from members of the ophthalmic community.These blogs are an opportunity for ophthalmic bloggers to engage with readers with about a topic that is top of mind, whether it is practice management, experiences with patients, the industry, medicine in general, or healthcare reform.
Study suggests potential link between semaglutide and risk of non ...
Jul 9, 2024 · Boston researchers led by first author Jimena Tatiana Hathaway, MD, MPH, reported that there is a potential risk of the development of non-arteritic ischemic optic neuropathy (NAION) 1 associated with prescriptions for semaglutide (Wegovy, Ozempic, Novo Nordisk). Prescriptions with semaglutide are FDA approved to treat obesity and type 2 diabetes, respectively.
Statin use may cause certain eye disorders, according to study
Dec 9, 2008 · Portland, OR-Eye disorders related to statin use were reported in the Jupiter Study led by F.W. Fraunfelder, MD, Casey Eye Institute, Oregon Health & Sciences University.The medication used to lower patients’ cholesterol levels, thus helping prevent coronary heart disease, stroke, and other deaths related to high cholesterol levels, is related to certain eye disorders in about 0.1% of patients.
Curing genetic blindness with space-enhanced artificial retinas
Dec 13, 2023 · Founded in 2009, LambdaVision is aiming to develop the world’s first cure for genetic blindness, and its looking to space for the answer. LambdaVision is designing and developing an innovative, protein-based artificial retina that utilizes a light-activated protein, bacteriorhodopsin, to restore functional sight to those who would otherwise be blind due to retinal degenerative diseases ...
Nicox publishes results of Phase 3 trial of NCX 470 for treatment …
Mar 20, 2024 · Nicox SA announced results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.. According to the company, NCX 470 is a novel NO-donating bimatoprost eye drop currently in Phase 3 ...
News - Ophthalmology Times
Wendy Lee, MD, an oculoplastics specialist and member of the program committee at EnVision Summit, shares an agenda that will include a mix of functional oculoplastics, aesthetics, and live facial rejuvenation demonstrations at the upcoming event, which will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.
FDA approves Bausch + Lomb’s enVista Envy range of IOLs
Oct 14, 2024 · Key Takeaways. enVista Envy IOLs provide a continuous range of vision with high dysphotopsia tolerance, enhancing cataract surgery outcomes. U.S. and Canadian trials showed high patient satisfaction, with minimal issues related to glare and close object viewing.